Minerva Neurosciences, Inc.

As of August 2, 2021, Minerva Neurosciences, Inc. is considered overvalued with a significant downgrade in investment appeal, reflected by a P/E ratio of 2.06 and a YTD decline of -20.33%, contrasting sharply with the S&P 500's gain of 2.44%.

As of May 27, 2025, the trend is mildly bearish due to daily moving averages indicating a bearish trend, while weekly indicators show mild bullishness, leading to a cautious outlook with a slight bearish bias.

As of March 2022, the management team of Minerva Neurosciences, Inc. includes Dr. Remy Luthringer (CEO and Executive Chairman), Mr. William Doyle (Lead Independent Director), and four Independent Directors: Mr. Hans Hasler, Ms. Jeryl Hilleman, Dr. David Kupfer, and Dr. Fouzia Laghrissi-Thode. They oversee the company's strategic direction and governance.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases, with a market cap of $12.87 million and a recent net profit of -$4 million.

As of Jun 18, Minerva Neurosciences, Inc. has a market capitalization of 12.87 million, with net sales of 0.00 million and a net profit of 6.26 million over the last four quarters. The balance sheet shows shareholder's funds of -25.69 million and total assets of 37.14 million.